24 related articles for article (PubMed ID: 19430287)
1. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics.
Bhavsar AR; Stockdale CR; Ferris FL; Brucker AJ; Bressler NM; Glassman AR;
Arch Ophthalmol; 2012 Jun; 130(6):809-10. PubMed ID: 22801859
[No Abstract] [Full Text] [Related]
2. One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.
Gutiérrez-Hernández JC; Caffey S; Abdallah W; Calvillo P; González R; Shih J; Brennan J; Zimmerman J; Martínez-Camarillo JC; Rodriguez AR; Varma R; Santos A; Sánchez G; Humayun M
Transl Vis Sci Technol; 2014 May; 3(4):8. PubMed ID: 25774328
[TBL] [Abstract][Full Text] [Related]
3. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center".
Erbahçeci IE; Ornek K
Retina; 2012 Jun; 32(6):1228; author reply 1228. PubMed ID: 22588354
[TBL] [Abstract][Full Text] [Related]
4. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
[TBL] [Abstract][Full Text] [Related]
5. We congratulate the authors for publishing their data on bilateral consecutive intravitreal injections administered in their office.
Shah GY; Ambatipudi S; Fernandes M; Lakshmipathy M; Varma PV; Sachdeva V; Pathengay A
Retina; 2010 Sep; 30(8):1325-6; author reply 1326-7. PubMed ID: 20827150
[No Abstract] [Full Text] [Related]
6. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
[TBL] [Abstract][Full Text] [Related]
7. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.
Bhavsar AR; Googe JM; Stockdale CR; Bressler NM; Brucker AJ; Elman MJ; Glassman AR;
Arch Ophthalmol; 2009 Dec; 127(12):1581-3. PubMed ID: 20008710
[TBL] [Abstract][Full Text] [Related]
8. Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients.
Matthews JL; Dubovy SR; Goldberg RA; Flynn HW
Ophthalmology; 2014 Mar; 121(3):702-8. PubMed ID: 24439760
[TBL] [Abstract][Full Text] [Related]
9. The article by Fintak et al on the incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
El-Ashry MF; Dhillon B
Retina; 2009 May; 29(5):720-1; author reply 721-2. PubMed ID: 19430287
[No Abstract] [Full Text] [Related]
10. Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
Moshfeghi AA
Semin Ophthalmol; 2011 May; 26(3):139-48. PubMed ID: 21609227
[TBL] [Abstract][Full Text] [Related]
11. POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS.
Reibaldi M; Pulvirenti A; Avitabile T; Bonfiglio V; Russo A; Mariotti C; Bucolo C; Mastropasqua R; Parisi G; Longo A
Retina; 2018 Jan; 38(1):1-11. PubMed ID: 28267115
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
